Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes

AIMS: The EMPA‐REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin. Overexpression and Ca(2+)‐dependent activation of Ca(2+)/calmodulin‐dependent kinase II (CaMKII) are hallmarks of HF, leading to contractile dysfun...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESC Heart Fail
Main Authors: Mustroph, Julian, Wagemann, Olivia, Lücht, Charlotte M., Trum, Maximilian, Hammer, Karin P., Sag, Can Martin, Lebek, Simon, Tarnowski, Daniel, Reinders, Jörg, Perbellini, Filippo, Terracciano, Cesare, Schmid, Christof, Schopka, Simon, Hilker, Michael, Zausig, York, Pabel, Steffen, Sossalla, Samuel T., Schweda, Frank, Maier, Lars S., Wagner, Stefan
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2018
Assuntos:
Short Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6073019/
https://ncbi.nlm.nih.gov/pubmed/30117720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12336
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados